quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 10, 2026

Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock?

View original at finance.yahoo.com
Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock? Wells Fargo & Company WFC is slated to report first-quarter 2026 earnings results on April 14, 2026, before market open…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Wells Fargo Q1 2026 earnings per share expected to be $1.57, representing 23.6% improvement from prior-year quarter

    60% confidence

  • Net interest income expected to be $12.3 billion in Q1 2026, indicating 6.9% rise from year-ago quarter

    60% confidence

  • Investment advisory and other asset-based fee revenues expected to be $2.9 billion in Q1 2026, indicating 12.8% year-over-year rise

    60% confidence

  • Wells Fargo has outpaced earnings consensus estimates in the trailing four quarters with average surprise of 7.53%

    60% confidence

  • Wells Fargo Q1 2026 revenues expected to reach $21.73 billion, representing 7.8% year-over-year growth

    60% confidence

  • Demand for commercial and industrial and consumer loans was impressive in the first two months of Q1 2026, while real estate loan demand was subdued

    60% confidence

  • Mortgage banking revenues expected to be $283 million in Q1 2026, suggesting 14.8% decline from year-ago level

    60% confidence

Data points we hold from this source

Wells Fargo & Company · mortgage banking revenues283 USD
Wells Fargo & Company · investment advisory fee growth12.8 percent
Wells Fargo & Company · net interest income growth6.9 percent
Wells Fargo & Company · investment advisory fees2.9 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock? — Source | Via News | pt.VIA.NEWS